Biotech Values

[mcbio]

Re: Roche/ITMN/(ACHN)

ITMN—I interpret the news as Roche’s agreeing to pay $175M merely to be free and clear of contractual obligations stemming from the 2006 Roche-ITMN partnership for HCV protease inhibitors. Inasmuch as there are newer and better PI’s available, I doubt that Roche will advance ITMN-191 to phase-3.

That ITMN-191 does not have what it takes is old news: e.g. #msg-46797334, #msg-53621981, #msg-53624063.

We are spot on in agreement here. No surprise given our prior discussion surrounding this topic (#msg-52705841). If we are right in our assumption, and one is to assume that Roche is still committed to the HCV space (and PIs in particular), then I interpret today's news as bullish for ACHN. If Roche wants another HCV PI, ACH-1625 is presumably the most advanced unpartnered HCV PI in the clinic having just started Phase 2. And of course it has QD dosing potential. Thoughts?